Abiomed Announces Preliminary Schedule of Events at TCT 2008

Abiomed Inc. (NASDAQ: ABMD), today announced its preliminary schedule of events at the Cardiovascular Research Foundation’s (CRF) annual Transcatheter Cardiovascular Therapeutics (TCT) scientific meeting, scheduled from Sunday, October 12, to Thursday, October 17, in Washington, D.C. at the Washington Convention Center.

Investor and Analyst Meeting

On Monday, October 13, Michael R. Minogue, Chairman, Chief Executive Officer and President; Daniel J. Sutherby, Chief Financial Officer; and Dr. Karim Benali, Chief Medical Officer, will host an investor and analyst meeting from 5:30 p.m. to 6:30 p.m. in the Constitution Ballroom at the Grand Hyatt Washington. The meeting agenda will consist of a thirty-minute presentation by Abiomed senior management providing an overview of the Impella^® 2.5 U.S. pivotal studies and details on the schedule of other Abiomed events at TCT 2008 including live cases, presentations and abstracts. Following the prepared remarks by Abiomed management, there will be a thirty-minute period for questions and open discussion.

Symposium and Clinical Presentations

On Monday, October 13, from 7:00 p.m. to 9:30 p.m., in the Constitution Ballroom at the Grand Hyatt Washington, Abiomed will also host an invitation-only symposium with presentations by leading clinicians including:

• Roxana Mehran, MD, FSCAI – Circulatory Support in the Cath Lab: Is there a new direction?
• William O’Neill, MD, FACC, FSCAI – Impella 2.5: From Anecdotal to Evidence Based Medicine
• Raed Aqel, MD, FACC: Impella Applications in Clinical Trials and Beyond
• Bartley Griffith, MD: Transitioning Circulatory Support from the Cath Lab to the Surgical Suite
• Moderator: Jeffery J. Popma, MD, FACC, FSCAI

At a later date, the Company plans to announce updated information and details on all Abiomed TCT 2008 events.

ABOUT ABIOMED

Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.

FORWARD-LOOKING STATEMENTS

This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and recently filed Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.